Aktuellt
SENASTE
Redeye provides an update in relation to Enzymatica’s Q4 2023 report. The report came in a bit under our expectations. Moreover, the company carries out a rights issue of SEK27.4m, which aligns with our estimate. Based on the report, we make some changes in our forecasts; however, the changes do not render an updated fair value range, including a base case of SEK6.
LÄS MER
